Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11211032 | 0.76 | MET (0.57) | KDM4EALDH1A1 | |
| SCHEMBL8350565 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5373208 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5359262 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14759162 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL14759243 | 0.74 | KDM4E (0.69) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24273206 | 0.73 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7983003 | 0.73 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24862850 | 0.73 | KDM4E (0.67) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23959346 | 0.71 | KDM4E (0.65) | KDM4EALDH1A1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673339-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7538120-B2 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1673339-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7511058-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7271178-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7230099-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007022529-A2 | METHOD OF TREATING INFLAMMATORY DISEASES | ARRAY BIOPHARMA INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7144907-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1673339-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060030610-A1 | Method of treating inflammatory diseases | ARRAY BIOPHARMA INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005023759-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA, INC. | 2005-03-03 | — | — | US | disclosed |
| US-4550166-A | SEDATIVES, TRANQUILIZERS, TENSION REDUCERS | AMERICAN CYANAMID COMPANY (US) | 1985-10-29 | — | — | US | disclosed |
| EP-0017438-B1 | SUBSTITUTED 3-ALKYL-6-PHENYL-1,2,4-TRIAZOLO(4,3-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN CYANAMID COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189649-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KDM4E 836/4885ALDH1A1 1431/4885RAB9A 186/4885 |
| US-20050049419-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KDM4E 875/4885ALDH1A1 1609/4885RAB9A 212/4885 |
| US-20060189808-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KDM4E 1179/4885ALDH1A1 1721/4885RAB9A 147/4885 |
| US-20050054701-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KDM4E 875/4885ALDH1A1 1609/4885RAB9A 212/4885 |
| US-20060030610-A1 | Method of treating inflammatory diseases | TNF, MPO, FABP2 | KDM4E 4266/4885ALDH1A1 408/4885RAB9A 2489/4885 |
| US-20060189668-A1 | Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK | NRAS, BRAF, RAF1 | KDM4E 1127/4885ALDH1A1 2351/4885RAB9A 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.